Generic Name: crizotinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Xalkori is a kinase inhibitor approved for the treatment of ALK- or ROS1-positive metastatic non-small-cell lung cancer (NSCLC) and for children and young adults with relapsed or refractory ALK-positive anaplastic large cell lymphoma.
Xalkori interferes with anaplastic lymphoma kinase (ALK), ROS1 and other receptor tyrosine kinases that play a role in cancer cell growth.
The PROFILE clinical trials showed that Xalkori improved response rates and delayed disease progression compared with chemotherapy in people with metastatic ALK-positive NSLC. The response rate was 66% in patients with metastatic ROS1-positive NSCLC. In study ADVL0912, 23 of 26 pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma responded (88%), with most achieving complete remission. Xalkori was first approved in 2011.
Xalkori is taken as a capsule twice daily.
Common adverse events include vision problems, nausea, vomiting, diarrhea, constipation, swelling, fatigue, decreased appetite, dizziness, neuropathy and elevated liver enzymes. More serious side effects may include severe liver toxicity, lung inflammation, heart rhythm abnormalities and severe vision loss. Xalkori can cause fetal harm if used during pregnancy.
For More Info: https://www.pfizerpro.com/product/xalkori/hcp
Patient Assistance Program Info: https://www.pfizerpro.com/product/xalkori/hcp/support/financial-assistance
Last Reviewed: January 17, 2021